Sapience Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sapience Therapeutics, Inc.
Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.
Kite licenses allogeneic cell technology from UCLA that may enable it to create off-the-shelf T-cell therapeutics, augmenting its ongoing development of autologous cancer therapies. See Scrip's monthly update on licensing agreements between companies and universities or other research institutions.
Derived from Strategic Transactions, Informa's premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced June through July 2016.
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.